血管生成素-2在肝细胞癌组织中的表达及其与预后的关系

Expression of angiopoietin-2 and prognosis in hepatocellular carcinoma

目的研究血管生成素-2（Ang-2）在肝细胞癌（HCC）组织中表达及其在判断预后中的价值。方法对随访的60例原发性肝癌临床资料进行回顾性分析，通过免疫组织化学方法检测Ang-2在癌组织中的表达情况。研究其与病理因素、组织学分化程度的相关性，并分析Ang-2表达与生存期的关系。结果Ang-2表达率为70％；Ang-2表达与病理因素无关（P〉0．05），与组织学分化程度相关（Х^2=5．424，P=0．025）；Ang-2高表达中低分化比例高（66．7％）。高表达组和低表达组患者的1、3、5年无瘤生存率分别为50．0％、33．3％、16．7％和89．6％、50．0％、25．0％（Х^2=6．477，P=0．021）。高表达患者无瘤生存期明显低于低表达患者。结论Ang-2表达多寡与HCC组织分化程度相关，与病理因素无关；Ang-2高表达者生存期低。Ang-2是肝癌切除术后判定预后的预测因子。

Objective To study the relationship between the expression of angiopoietins-2 （Ang-2） and prognosis in hepatocellular carcinoma （HCC） after hepatic resection. Methods Sixty patients with primary liver cancer were retrospectively analyzed and the expression of Ang-2 in carcinoma tissues were assayed by immunohistochemical staining. The interrelationships among the expression of Ang-2, clinicopathological factors and the grade of differentiation of HCC cells were studied. The relationship between the expressions Of Ang-2 and survival time was analysed. Results The expression rate of Ang-2 was 70%. Ang-2 staining had no correlation with clinicopathological factors （ P 〉 0.05 ）, but it had a significant correlation with the grade of differentiation of HCC＇cells （ Х^2 = 5. 424, P = 0. 025 ）. Ang-2 of moderately and poorly differentiated HCC were higher （66.7%） than those of well-differentiated HCC. The disease-free survival rates of patients with high Ang-2 expression and low Ang-2 expression were 50% （1-year）, 33.3% （3-year）, 16.7% （5-year）and 89.6% （1-year）, 50.0% （3-year）, 27.1% （5-year）, respectively. The disease-free survival of patients with high Ang-2 expression were significantly less than those of patients with low Ang-2 expression （ Х^2 = 6. 477, P = 0. 021 ）. Conclusion The expressions of Ang-2 are correlated with the grade of differentiation of HCC cells, but are not correlate with clinicopathological factors. The survivals of patients with Ang-2 high expression are lower than those of low expression. Ang-2 is a significant predictive factor for recurrence after hepatic resection in HCC patients.